Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erythropoietin messenger RNA is an **mRNA-based drug concept** in which synthetic messenger RNA encoding erythropoietin is delivered to host cells so they transiently produce erythropoietin protein in vivo. The intended pharmacology is functional replacement of erythropoietin, leading to activation of the erythropoietin receptor on erythroid progenitors and stimulation of erythropoiesis. This has been described in preclinical literature as a protein-replacement approach and proof-of-concept mRNA therapeutic, but the queried name does not clearly identify a single clinically established product, branded medicine, or uniquely attributable development candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on erythropoietin messenger RNA.